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Quantitative biology offers enormouspotential in the biomedical sciences
through the use of mathematical models.
These models are indispensable for under-
standing nonlinear systems, which are char-
acterized by feedbacks that produce outputs
that are not proportional to their inputs.1
In this issue of Immunology & Cell
Biology, Sugarman et al.2 present a mathe-
matical model of a peptide-major histo-
compatibility complex (pMHC)-nanoparticle
(NP)-based therapy for Type 1 diabetes
(T1D) to understand and optimize treat-
ment conditions in the non-obese diabetic
(NOD) mice. This model exemplifies both
the surprising behavior of nonlinear systems
and the power of quantitative biology in
medicine.
Defects in memory autoregulatory CD8þ
T-cell homeostasis, peripheral activation and
function play a role in the chain of events
leading to islet autoimmunity in T1D. The
ability to actively suppress a beta cell-specific
autoimmune response makes autoregulatory
CD8þ T cell an attractive therapeutic alter-
native for treating T1D. Autoregulatory
CD8þ T cells originate from naive low-
avidity T-cell precursors and can be expan-
ded using NPs coated with specific pMHC
Class I complexes.2
The mathematical model of Sugarman
et al.2 describes the effects of the thera-
peutic efficacy of NP treatment on three
populations of CD8þ T cells: reactive
memory autoregulatory T-cells, reactive
high-avidity effector T-cells and effector islet-
specific autoreactive T-cells. A population of
antigen-presenting cells (APCs) expressing
IGRP206-214-MHC is also included to reflect
their deletion by autoregulatory T-cells. They
relied on one factor to investigate the thera-
peutic efficacy of NP treatment: the dose of
NPs coated with specific pMHC Class I
complexes. After estimating the parameters
that describe the rates of change of the APC
and three T-cell populations in the average
mouse, Sugarman et al.2 performed a
systematic analysis of the model.
Sugarman et al.2 discovered that the
mathematical average mouse model can
exhibit two equilibrium states, which
depend on the pMHC-NP concentration
(Figure 1). The first is a healthy state, in
which the total effector T-cell population is
extinct. The second is an autoimmune state,
in which the total effector autoreactive T-cell
population is elevated. This result is in
agreement with previous models by Khadra
et al.3,4 and the presence of healthy and
diabetic individuals in the NOD mice
model population following boosting of
memory-like autoregulatory T cells.5 The
surprising model result comes from
increasing the pMHC valency (expression
level of pMHC) in the NPs. There is a
valency threshold (442.5mg) that abruptly
and discontinuously destroys the
autoimmune equilibrium state, creating
only one equilibrium state in the
population: a healthy state (Figure 1). Immu-
nologically this result suggests that there is a
threshold value of pMHC-NP optimal dose
in NP-dependent expansion rate of autore-
gulatory T-cell population leading to a sig-
nificant increase in the treatment efficacy.
This abrupt change in the model behavior is
‘the last straw that breaks the camel’s
back’, something typically observed in
nonlinear systems.1 The model analysis
shows that the effectiveness of the p-MHC-
NP therapy relies on two important factors:
(i) the expansion of CD8þ memory
autoregulatory T-cells that are reactive to
the pMHC complex coated onto the NPs,
and (ii) the ability of this pool of
autoregulatory T-cells to delete APCs
expressing the same pMHC. Both factors
are responsible for the nonlinear behavior
reported in Sugarman et al.2
The majority of the quantitative biology
models in the literature are limited to the
investigation of the behavior of the average
organism. To avoid this limitation, Sugarman
et al. expanded their analysis by considering a
population of 100 ‘model mice’. Each ‘mouse
model’ has a set of random parameter values
and initial conditions from physiologically
reasonable ranges, which display heterogene-
ity within the mouse population. The analy-
sis shows that around 81% of the mice are
responsive to the treatment, while 19% are
nonresponsive. In both the response and
nonresponsive groups, the pMHC-NP treat-
ment leads to an increase in the size of the
CD8þ NRP-V7 reactive memory autoregu-
latory T-cell population, and a decline in the
size of both the CD8þ NRP-V7 reactive
high-avidity effector T-cell population, and
CD8þ effector islet-specific autoreactive
T-cell population. However, there are some
significant quantitative differences between
the responsive and nonresponsive model
mice. After analyzing such differences,
Sugarman et al.2 find that there is a
minimum threshold in the size of memory
autoregulatory T-cell population that must
be in circulation for the pMHC-NP
treatment to be effective at a given dose,
inter-injection interval and pMHC valency.
Interestingly, they also found that maxi-
mizing the expression level of pMHC on
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NPs (pMHC valency) improves treatment
outcomes in the NOD mice more than
increasing the nanoparticule dose.
All mathematical modeling is a simplifica-
tion of one type or another. The model of
Sugarman et al.2 is focused on three popu-
lations of CD8þ T cells, which expand or
reduce in respond to stimulation to pMHC
class I complexes in NPs. However, there is a
sequential hierarchy of CD8þ cells in reacti-
vity to islet autoantigens in the NOD.6 The
authors are aware of this limitation and
provide a discussion. For example, the
elimination of autoimmune responses to
insulin prevents the development of the
disease in NOD mice. In contrast, transgenic
overexpression of islet-specific glucose-6-
phosphatase catalytic-subunit-related protein
(IGRP) resulted in loss of intra-islet IGRP-
specific T cells but did not protect NOD mice
from insulitis or T1DM. These data provide
supporting evidence that T-cell responses
against IGRP are downstream of the
response to proinsulin,6 at least when
applying a transgenic mouse approach.
The major challenge going forward is to
prove the existence of CD8þ reactive mem-
ory autoregulatory T cells in humans. Con-
verging lines of evidence demonstrate that
immunoregulatory dendritic cells (DC) exist
that can promote Treg development
both in vitro and in vivo.7 It is not clear
if DCs exert a similar effect on memory
autoregulatory T cells. In addition, the
antigen-specific expansion of memory
autoregulatory T cells and other regulatory
T-cell subpopulation to suppress ongoing
pathogenic responses could also depend on
a number of additional critical issues that
may need to be addressed and introduced
into future models. For example,
 Do regulatory T cells in the NOD
mouse model increase the avidity of
primary CD8þ T-cell responses and pro-
mote memory?
 What are the mechanisms by which auto-
regulatory cells exert their action, for
example, regulating DCs, indoleamine
2,3-dioxygenase (IDO), interleukin-34?
 Do memory autoregulatory T cells
expanded by NPs coated with specific
pMHC Class I complexes have a unique
ability to cause a ‘cascade’ suppressive
effect by creating a regulatory milieu that
promotes development of additional mem-
ory autoregulatory T cells?
 How do specific pMHC Class I complexes
block effector T-cell function?
Owing to the complexity of the autoim-
mune response in TD1, quantitative model-
ing can be used to understand complex
immunological signals and system-level pro-
cesses that are difficult to interrogate via
experimental methods alone. The model of
Sugarman et al.2 is an excellent starting point.
It also demonstrates that a simple model can
show surprising behaviors. To understand
more complex models, unaided experimen-
tal intuition is not enough: future
collaborative efforts between experimental
immunologists and quantitative biologists
will be essential to understand the
mechanisms of the immune response and
improve treatment outcomes in autoimmune
diseases.
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Figure 1 The reactive memory autoregulatory T-cells arise from the autoantigenic stimulation with
nanoparticles coated with pMHC class I complexes. According to the model of Sugarman et al.,2 this
will occur with both non-effective and effective treatments. The optimal treatment is a function of
nanoparticle doses, inter-injection interval and the expression level of pMHC on nanoparticles. In a
non-effective treatment regime (a), the NOD average model mice can exhibit either an autoimmune or
a healthy phenotype. In the autoimmune state, the total effector T-cell population is elevated. In the
healthy phenotype, the total effector T-cell population is extinct. In contrast, the healthy state is the
only possible state in an effective treatment regime (b).
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